Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.55 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocyte progenitor cells (835 nCPM) | 1.00 |
| chemistry Open Targets | compounds already reach it: dronedarone hydrochloride, orphenadrine hydrochloride, quinidine gluconate +69 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 1 stopped | 0.80 |
| literature PubMed | 16 Parkinson's papers of 1,848 | 0.63 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11462
Earlier readings: 2026-10-26 0.51; 2026-10-25 0.51; 2026-10-24 0.51; 2026-10-23 0.51.
Sealed predictions
- SCN1A in oligodendrocytes, braak+0.47 (p 0.197) → -0.47 (p 0.207)receipt 0591
- SCN1A in dopamine neurons, braak+0.11 (p 0.784) → +0.69 (p 0.038)receipt 0592
- SCN1A in oligodendrocytes, resilience-0.08 (p 0.807) → +0.19 (p 0.468)receipt 0136
- SCN1A in oligodendrocytes, braak-0.03 (p 0.863) → -0.11 (p 0.469)receipt 0135
Swarm cases
receipt 0592: SCN1A in dopamine neurons, braak
- power
- full sample +0.38 (p 0.116, n 18), 95% CI -0.10 to +0.72. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.38 (p 0.116, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.42 (p 0.080, n 18). could be the mix.
- skeptic
- leave-one-out range +0.31 to +0.50, sign flips 0; without severely affected donors +0.38 (p 0.116, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCN1A in dopamine neurons.
case closed: nothing better to follow up.
receipt 0591: SCN1A in oligodendrocytes, braak
- power
- full sample -0.03 (p 0.894, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.969, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.05 (p 0.847, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.11, sign flips 5; without severely affected donors -0.03 (p 0.894, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCN1A in oligodendrocytes.
case closed: nothing better to follow up.
receipt 0136: SCN1A in oligodendrocytes, resilience
- power
- full sample -0.01 (p 0.966, n 55), 95% CI -0.27 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: -0.07 (p 0.736, n 55). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis -0.52 (p 0.0075); controlling for it: -0.05 (p 0.801, n 55). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.09, sign flips 19; without severely affected donors -0.10 (p 0.616, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for SCN1A in oligodendrocytes.
case closed: nothing better to follow up.
receipt 0135: SCN1A in oligodendrocytes, braak
- power
- full sample -0.09 (p 0.418, n 84), 95% CI -0.30 to +0.13. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: -0.07 (p 0.518, n 84). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.09 (p 0.422); controlling for it: -0.08 (p 0.472, n 84). could be the mix.
- skeptic
- leave-one-out range -0.12 to -0.06, sign flips 0; without severely affected donors +0.04 (p 0.743, n 75). fragile.
- cell type
- strongest in GABA neurons: +0.31 (p 0.0040, n 84) vs -0.09 in oligodendrocytes. proposing GABA neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCN1A in oligodendrocytes.
follow-up registered; not confirmed in ventral tegmental area.
follow-up SCN1A · GABA neurons · braak: ventral tegmental area +0.11 p 0.317 (needs p < 0.0025)
Receipts
loading the receipts